Amorce

The science

Not 400 links. Three honest states of knowledge, the gaps nobody has filled yet, then the studies themselves, explained.

What we know

Replicated, large, or agreed by international consensus.

  • ADHD is a valid neurodevelopmental condition found across countries and cultures.

    Faraone et al. 2021
    1. Consensus statement Faraone SV, Banaschewski T, Coghill D, et al. (80 authors) (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. Open source ↗Only included findings from meta-analyses or studies with more than 2,000 participants.
  • It is highly heritable (~74%) and highly polygenic — thousands of variants, each with a tiny effect.

    Faraone et al. 2019 +1
    1. Narrative review Faraone SV, Larsson H (2019). Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry, 24, 562–575. Open source ↗Mean heritability ≈ 74% across twin studies.
    2. Cohort / register study Demontis D, Walters GB, Athanasiadis G, et al. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics, 55, 198–208. Open source ↗38,691 people with ADHD and 186,843 controls; mostly European ancestry.
  • It often persists into adulthood: about 2.6% of adults have persistent ADHD.

    Song et al. 2021
    1. Meta-analysis Song P, et al. (2021). The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. Journal of Global Health, 11, 04009. Open source ↗Persistent adult ADHD 2.58%; symptomatic adult ADHD 6.76%.
  • Medication reduces core symptoms in the short term for many children and adults.

    Cortese et al. 2018 +1
    1. Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
    2. Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
  • Emotional dysregulation is common in ADHD, even though it isn’t a diagnostic criterion.

    Shaw et al. 2014 +1
    1. Narrative review Shaw P, Stringaris A, Nigg J, Leibenluft E (2014). Emotion dysregulation in attention deficit hyperactivity disorder. American Journal of Psychiatry, 171(3), 276–293. Open source ↗Emotion dysregulation in about 25–45% of children and 30–70% of adults with ADHD.
    2. Meta-analysis Beheshti A, Chavanon M-L, Christiansen H (2020). Emotion dysregulation in adults with attention deficit hyperactivity disorder: a meta-analysis. BMC Psychiatry, 20, 120. Open source ↗13 studies, 2,535 participants; large difference (g ≈ 1.17).
  • Girls and women are diagnosed later and less often than boys and men.

    Martin et al. 2024
    1. Cohort / register study Martin J, et al. (2024). Sex differences in attention-deficit hyperactivity disorder diagnosis and clinical care: a national study of population healthcare records in Wales. Journal of Child Psychology and Psychiatry, 65(12), 1648–1658. Open source ↗16,458 people diagnosed with ADHD.

What we’re still figuring out

Research exists, but it’s incomplete or inconsistent.

  • Which psychological treatments work best for adults, and for whom. Effects are inconsistent across trials.

    Ostinelli et al. 2025 +2
    1. Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
    2. Randomised trial Safren SA, Sprich S, Mimiaga MJ, et al. (2010). Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA, 304(8), 875–880. Open source ↗86 adults already on medication; 12 weekly sessions.
    3. Randomised trial Solanto MV, Marks DJ, Wasserstein J, et al. (2010). Efficacy of meta-cognitive therapy for adult ADHD. American Journal of Psychiatry, 167(8), 958–968. Open source ↗88 adults; 12 weekly group sessions on time management, organisation and planning vs supportive therapy.
  • How timing and “time blindness” show up in adults, not just children.

    Mette 2023 +1
    1. Narrative review Mette C (2023). Time perception in adult ADHD: findings from a decade — a review. International Journal of Environmental Research and Public Health, 20(4), 3098. Open source ↗Very few adult studies; results mixed.
    2. Meta-analysis Marx I, Cortese S, Koelch MG, Hacker T (2022). Meta-analysis: altered perceptual timing abilities in attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 61(7), 866–880. Open source ↗55 studies, mostly children and adolescents.
  • Whether ADHD can genuinely begin in adulthood.

    Moffitt et al. 2015 +1
    1. Cohort / register study Moffitt TE, Houts R, Asherson P, et al. (2015). Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. American Journal of Psychiatry, 172(10), 967–977. Open source ↗Dunedin cohort; most adult cases had no childhood diagnosis.
    2. Cohort / register study Sibley MH, Rohde LA, Swanson JM, et al. (2018). Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. American Journal of Psychiatry, 175(2), 140–149. Open source ↗Many apparent "late onset" cases were explained by other conditions or substance use.
  • How sex hormones interact with ADHD symptoms across the menstrual cycle and midlife.

    Osianlis et al. 2025 +1
    1. Systematic review Osianlis E, Thomas EHX, Jenkins LM, Gurvich C (2025). ADHD and sex hormones in females: a systematic review. Journal of Attention Disorders. Open source ↗11 studies; only 6 with a formal ADHD diagnosis; none empirically studying menopause.
    2. Cohort / register study Jakobsdóttir Smári U, et al. (2025). Perimenopausal symptoms in women with and without ADHD: a population-based cohort study. European Psychiatry. Open source ↗5,392 Icelandic women aged 35–55; ADHD self-reported; cross-sectional analysis.
  • Why executive-function problems appear in some people with ADHD but not others.

    Willcutt et al. 2005 +1
    1. Meta-analysis Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF (2005). Validity of the executive function theory of ADHD: a meta-analytic review. Biological Psychiatry, 57(11), 1336–1346. Open source ↗83 studies. Moderate group differences; fewer than half of people with ADHD show impairment on any given executive task.
    2. Narrative review Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJS (2005). Causal heterogeneity in ADHD: do we need neuropsychologically impaired subtypes?. Biological Psychiatry, 57(11), 1224–1230. Open source ↗Different people with ADHD may get there through different routes.

What we don’t know

Big open questions without reliable answers yet.

  • How genes lead, step by step, to the everyday experience of ADHD.

    Demontis et al. 2023
    1. Cohort / register study Demontis D, Walters GB, Athanasiadis G, et al. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics, 55, 198–208. Open source ↗38,691 people with ADHD and 186,843 controls; mostly European ancestry.
  • The long-term effects of treatment over decades — on work, relationships, health.

    Ostinelli et al. 2025
    1. Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
  • How to predict which treatment will work for a particular person.

    Cortese et al. 2018
    1. Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
  • How ADHD changes through menopause — there are almost no studies.

    Osianlis et al. 2025
    1. Systematic review Osianlis E, Thomas EHX, Jenkins LM, Gurvich C (2025). ADHD and sex hormones in females: a systematic review. Journal of Attention Disorders. Open source ↗11 studies; only 6 with a formal ADHD diagnosis; none empirically studying menopause.
  • Whether popular strategies like body doubling or Pomodoro help people with ADHD.

    Body-doubling EEG study 2025
    1. Cross-sectional study See original article (2025). Reading between the lines: exploring body doubling in ADHD using EEG. Proceedings of ACM SIGACCESS ASSETS 2025. Open source ↗Small study; no significant difference versus working alone.

Research gaps

Who and what has been studied too little.

Women

Most foundational studies were in boys. Hormones, contraception and menopause are barely studied.

Osianlis et al. 2025 +1
  1. Systematic review Osianlis E, Thomas EHX, Jenkins LM, Gurvich C (2025). ADHD and sex hormones in females: a systematic review. Journal of Attention Disorders. Open source ↗11 studies; only 6 with a formal ADHD diagnosis; none empirically studying menopause.
  2. Consensus statement Kooij JJS, Bijlenga D, Salerno L, et al. (2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 56, 14–34. Open source ↗Notes the lack of research on sex and gender differences.
Older adults

Prevalence falls with age in studies, but very few studies include people over 60.

Song et al. 2021
  1. Meta-analysis Song P, et al. (2021). The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. Journal of Global Health, 11, 04009. Open source ↗Persistent adult ADHD 2.58%; symptomatic adult ADHD 6.76%.
Non-European populations

The largest genetic studies are mostly of European ancestry; most trials are from North America and Europe.

Demontis et al. 2023
  1. Cohort / register study Demontis D, Walters GB, Athanasiadis G, et al. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics, 55, 198–208. Open source ↗38,691 people with ADHD and 186,843 controls; mostly European ancestry.
Everyday outcomes

Trials mostly measure symptom scores, not whether people can start tasks, keep jobs or feel better.

Ostinelli et al. 2025
  1. Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
Long-term follow-up

Most treatment trials last weeks to months.

Cortese et al. 2018
  1. Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
Individual differences

Group averages hide large variation. We can’t yet predict who benefits from what.

Nigg et al. 2005
  1. Narrative review Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJS (2005). Causal heterogeneity in ADHD: do we need neuropsychologically impaired subtypes?. Biological Psychiatry, 57(11), 1224–1230. Open source ↗Different people with ADHD may get there through different routes.

Emerging research

  • Rare genetic variants with larger effects are now being identified alongside common ones.

    Rare-variant study (Nature) 2025 +1
    1. Cohort / register study See original article (2025). Rare genetic variants confer a high risk of ADHD and implicate neuronal biology. Nature. Open source ↗Rare variants with larger effects, alongside common variants.
    2. Cohort / register study Demontis D, Walters GB, Athanasiadis G, et al. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics, 55, 198–208. Open source ↗38,691 people with ADHD and 186,843 controls; mostly European ancestry.
  • Cycle-informed approaches to ADHD care are being explored in small studies.

    Kennedy et al. 2026
    1. Systematic review Kennedy G, Baran-Goldwax M, Lippé S (2026). Menstrual health and attention-deficit/hyperactivity disorder (ADHD) symptoms: a scoping review. Women’s Health. Open source ↗20 studies (2014–2025); most under 200 participants.
  • Digital and app-delivered CBT for adults is being tested in randomised trials.

    Antshel et al. 2025
    1. Randomised trial Antshel KM, McBride H, Knouse LE (2025). Bridging the gap: digital CBT for adults managing ADHD challenges. Journal of Attention Disorders. Open source ↗154 adults, 8 weeks, compared with a waitlist (which tends to overestimate effects).

Go to the studies